Hazel Jones

Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.

Deanne K. Thompson, S. Wren, Irina S. Chuckowree, 2004, Journal of medicinal chemistry.

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

I. Stratford, T. Illidge, R. Wilkinson, 2014, Cancer research.

The role of mouse tumour models in the discovery and development of anticancer drugs

C. Ireson, A. Palmer, M. Alavijeh, 2019, British Journal of Cancer.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Simon J. Dovedi, D. Greenawalt, Dennis Wang, 2016, Cancer Immunology Research.

Clinical development of new drug–radiotherapy combinations

Richard A. Adams, Kevin J. Harrington, Maria A. Hawkins, 2016, Nature Reviews Clinical Oncology.

Unblocking the cancer drug development bottleneck via innovative partnering.

Robert J. Williams, J. Ritchie, Hazel Jones, 2016, Future oncology.

FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.

M. Knowles, P. Loadman, C. Twelves, 2016 .

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

I. Stratford, T. Illidge, R. Wilkinson, 2014, Cancer research.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

D. Greenawalt, Dennis Wang, R. Sainson, 2016, Cancer Immunology Research.